Q2 Results: Sun Pharma Sales Up By 10% YoY, Records Net profit Of 2,262 Cr
The Indian pharmaceutical giant Sun Pharma reported its quarter two earnings on Tuesday, the pharma major has recorded gross sales worth of Rs 10,809 crores for the quarter that ended in September 2022, a 13.1 per cent rise over the same quarter in the previous year.
The company’s sales in India saw a jump of 8.5 per cent to Rs 3,460 crore, a rise of 8.5 per cent against the second quarter of last year. At the same time, the sales in the US were up by 27.5 per cent quarter on quarter and stood at USD 200 million.
The pharma company recorded a 12.4 per cent rise year on year in EBTIDA and stood at Rs 2,956 crores, while the EBTIDA margins for the second quarter saw a drop of 0.3 per cent, it was recorded at 27 per cent compared to the corresponding quarter last year.
Sun pharma’s R&D investments also saw a boost in the September quarter, it was recorded at Rs 571 crores, an increase of 35 crores over the same quarter last year.
“For Q2, we recorded double-digit topline growth and strong margins driven by market share gain in India, sustained ramp-up of our global specialty business and growth in Emerging Markets. Global specialty business has grown by 27.5 per cent driven by Ilumya, Cequa and Winlevi. We continue to focus on expanding our global specialty business and growing all our businesses,” said Dilip Shanghvi, Managing Director, Sun Pharma.
